Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.
You may also be interested in...
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations first day of the meeting.
The company has developed a technology that uses engineered DNA to reprogram cancer cells, forcing them to produce substances that could be used to help image, detect or even destroy them.
The Glasgow-based company has completed a large series A round to further develop its technology, which can be used to help save patients’ lives in the event of opioid overdose. Medtech Insight spoke to the Scottish National Investment Bank, one of the main investors, about the deal and its altruistic view of investment.